Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) are up significantly in the pre-market this morning following the company’s announcement that they have achieved disease-free outcomes in pateints with genetic diseases during their ongoing BP-004 Phase 1/2 clinical trial. The announcement came at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida this weekend.
“These interim results present strong evidence that the addition of BPX-501 modified donor T cells provides important immune support and improves outcomes in patients undergoing a T-depleted haploidentical stem cell transplant,” said lead investigator Dr. Franco Locatelli, Director, Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù.
Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) are trading up $2.10 or 9.68% in the pre-market. The stock closed at $21.7 during the last trading session. It is down 6.02% since May 4, 2015 and is downtrending. It has underperformed the S&P500 by 5.82%.
From a total of 3 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) stock, 2 rate it a “Buy”, 1 a “Sell”, and 0 a “Hold”. This means that 67% of the ratings are positive. Bellicum Pharmaceuticals Inc was the topic of 4 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. Zacks downgraded shares on September 21 to a “Sell” rating. Citigroup initiated BLCM stock in a recent report from July 24 with a “Buy” rating.
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $575.07 million. The Firm is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. It currently has negative earnings. The Firm is using its chemical induction of dimerization technology platform to engineer and then control components of the immune system in real time.